Clinical trials: Breast Neoplasms, completed
Breast Cancer
The Impact of Preoperative Breast MRI in Patients With Breast Cancer Selected for Breast Conserving Surgery
The purpose of this prospective observational study is to evaluate the impact of preoperative breast MRI in patients with breast cancer selected for breast- conserving surgery.
- Trial name
- NCT01391806
- Where
- Norway
- Volunteers
- 145 people
- Sponsor
- Nordlandssykehuset HF
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Breast Cancer, Breast Neoplasms
The Unmet Needs and the Workplace Reintegration of Breast Cancer Patients: the NEW-BreCa Project
Breast cancer (BC) have unmet needs that can impact negatively on participation in meaningful activities and the overall quality of life, if not addressed by the healthcare services.
- Trial name
- NEW-BreCa (NCT05309252)
- Where
- Italy
- Volunteers
- 113 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Breast Cancer
Integrative Oncology Outcomes Study in Breast Cancer
This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on…
- Trial name
- IO-OS-BC (NCT01366248)
- Where
- 6 sites in United States
- Volunteers
- 750 people
- Sponsor
- Bastyr University
Breast Cancer
Digital Breast Tomosynthesis Preference Study
Mammography remains the current standard in the detection of breast cancer. However, conventional two-view mammography will not detect all cancers.
- Trial name
- NRR (NCT00776126)
- Testing
- Digital Breast Tomosynthesis Exam
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
This phase II trial studies how well hypofractionated radiation therapy works in treating participants with breast cancer before surgery.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
- Trial name
- NCT03624478
- Testing
- Hypofractionated Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Breast Neoplasms
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell…
- Trial name
- BREAST-HDCT (NCT02860585)
- Where
- France
- Volunteers
- 235 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
The Health of Women Study
The HOW Study is a first-of-its-kind international online study for women and men with and without a history of breast cancer. The investigators will collect information about your health, your job, your diet, and your family…
- Trial name
- HOW (NCT02334085)
- Where
- United States
- Volunteers
- 55,008 people, healthy volunteers welcome
- Sponsor
- Dr. Susan Love Research Foundation
Breast Cancer Risk
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer
This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients.
- Trial name
- NCT03688204
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- Ambry Genetics
Healthy Adults
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
The purpose of the study is to see and learn the effect of multiple doses of a strong CYP3A4 inhibitor and a potent UGT2B7 inhibitor on the PK of PF-07220060.
- Trial name
- NCT07160738
- Testing
- PF-07220060, Itraconazole, Probenecid
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01853748
- Testing
- Trastuzumab, Paclitaxel, Trastuzumab emtansine
- Where
- 85 sites in United States
- Volunteers
- 512 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
- Trial name
- NCT00166543
- Testing
- TAS-108
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- SRI International
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Breast Cancer, Lymphedema
Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer
RATIONALE: Diagnostic procedures, such as single-photon emission computed tomography and computed tomography lymphoscintigraphy, may help lower the dose of radiation therapy after surgery, and help prevent lymphedema.
- Trial name
- NCT00743314
- Testing
- screening questionnaire administration, computed tomography, lymphoscintigraphy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
Early Stage Breast Cancer
A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)
In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates for breast cancer patients. Improvements in outcomes, however, are compromised by the considerable toxicities associated with…
- Trial name
- React-G (NCT02428114)
- Where
- 2 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
TC Avastin. ICORG 08-10, V6
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00911716
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- 8 sites in Denmark, Ireland
- Volunteers
- 106 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+).
- Trial name
- ADAPT; T-DM1 (NCT01745965)
- Testing
- T-DM1, Trastuzumab
- Where
- 2 sites in Germany
- Volunteers
- 380 people
- Sponsor
- Women's Cancer Study Group GmbH
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.